The nomination committee appointed before Bioservo's annual general meeting in 2023

In line with the decision taken during the Annual General Meeting on May 3, 2022, Bioservo’s Chairman of the Board has contacted the company's largest owners to form a nomination committee. Counted as an owner is also a group of two or more shareholders (shareholder group) if they have notified the Chairman of the Board that they wish to participate in the work of the nomination committee together.

The following shareholders and representatives are part of the Nomination Committee, in addition to Chairman Anders Lundmark:

• Runar Bjørklund, nominated by Tellacq AB, chairman of the election committee
• Tomas Ward, representative of own holding
• Staffan Östlin, nominated by Adrigo Asset Management

The Nomination Committee shall submit proposals to the Chairman of the Annual General Meeting 2023 regarding the following:

• Proposal for members of the Board of Directors
• Proposal for the auditor
• Proposal for the Chairman of the Board
• Proposal regarding the Board remuneration, divided for the chairman and for other members of the board as well as remuneration for committee work
• Proposed remuneration to the auditor
• Proposal for Chairman of the Annual General Meeting
• Guidelines for appointment of the election committee

Shareholders who wish to submit proposals to the Nomination Committee for the Annual General Meeting 2023 may do so to the Nomination Committee no later than February 28, 2023 by emailing to [email protected] or by posting a letter addressed to Bioservo Technologies AB, Nomination Committee, Torshamnsgatan 35, 164 40 Kista.

About Bioservo Technologies
Bioservo Technologies AB (publ) is a world leading company in wearable muscle strengthening systems for people in need of extra strength and endurance. All our innovative products and systems are designed to keep people strong, healthy, and efficient. The company has a unique global position within soft exoskeleton technology for the hand, both for industrial applications to improve the health for workers and to improve quality of life for people with reduced muscle strength. Bioservo Technologies was founded in 2006 in collaboration between researchers at the Royal Institute of Technology and a doctor at Karolinska University Hospital. Bioservo Technologies is a Swedish public limited company with headquarters in Stockholm.

FNCA Sweden AB is the company’s Certified Adviser on Nasdaq First North
For more information, please visit www.bioservo.com